Projecting the yearly mortality reductions due to a cancer screening programme

Area of Science:

• Epidemiology
• Biostatistics
• Public Health

Background:

• Cancer screening program decisions involve balancing benefits against harms and costs.
• Current evidence often relies on single-number summaries (e.g., overall mortality reduction) from trials, which can be problematic for projecting long-term impacts.
• Traditional summaries may not fully capture the timing, magnitude, and duration of mortality benefits.

Purpose of the Study:

• To propose a novel method for assessing the mortality impact of cancer screening programs.
• To introduce the use of rate ratio curves and their complement, mortality reduction curves, for a more comprehensive evaluation.
• To provide a framework for comparing different screening strategies based on their mortality reduction patterns.

Main Methods:

• Utilizing rate ratio curves derived from screening trial data.
• Calculating complementary mortality reduction curves to visualize benefits over time.
• Illustrating the computation and application of these curves using screening trial data.

Main Results:

• Rate ratio curves and mortality reduction curves offer an interpretable way to understand the timing, magnitude, and duration of mortality benefits from screening.
• These curves allow for a more nuanced comparison of different screening regimens than traditional single-number summaries.
• The method facilitates projections of yearly mortality reductions from sustained screening programs.

Conclusions:

• Rate ratio curves and mortality reduction curves are valuable tools for evaluating cancer screening programs.
• These methods provide a clearer understanding of the dynamic impact of screening on cancer mortality.
• Encouraging trialists to report data suitable for generating these curves will improve evidence-based decision-making for cancer screening implementation.